Navigation Links
Lilly to Acquire SGX Pharmaceuticals
Date:7/8/2008

Deal Expands Lilly's Structure-Based Drug Discovery Capabilities

INDIANAPOLIS, and SAN DIEGO, July 8 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) and SGX Pharmaceuticals, Inc. (Nasdaq: SGXP) today announced that the companies have signed a definitive merger agreement providing for the acquisition of SGX in an all-cash transaction. SGX, based in San Diego, California, is a biotechnology company focused on drug discovery and development in the area of oncology. Under the terms of the agreement, Lilly will acquire all of the outstanding shares of SGX common stock at a price of $3.00 per share, for a total purchase price of approximately $64.0 million.

The acquisition will allow Lilly to integrate SGX's structure-guided drug discovery platform into its drug discovery efforts. It will also give Lilly access to FAST(TM), SGX's fragment-based, protein structure guided drug discovery technology, and to a portfolio of pre-clinical oncology compounds focused on a number of high-value kinase targets.

Since entering into an initial collaboration in 2003, Lilly has partnered with SGX to determine 3-dimensional structures of key Lilly drug targets utilizing SGX's proprietary x-ray crystallography technology. The ongoing collaboration also provides Lilly with access to the SGX synchrotron beamline facility, SGX-CAT, which is a state-of-the-art synchrotron facility enabling X-ray crystallography and protein structure determination built by SGX at the Advanced Photon Source (APS) located at the Dep
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Lillys Connelly Appointed to the Presidents Commission on White House Fellowships
2. Lilly Employees from Nearly 50 Nations Participate in Companys First-Ever Global Day of Service
3. Lilly Backs Federal Legislation to Inform the Public on Payments to Physicians
4. Lilly Completes Final Phase of Its Indianapolis Biotechnology Complex
5. Lilly CEO Urges Policy Prescriptions to Help Ensure Public and Private Biotech Investments Generate Dividends and U.S. Job Growth
6. Lilly CEO Praises Massachusetts Leadership in Biotech, Urges Policy Prescriptions to Help Ensure States Investment Generates Dividends and Jobs
7. Lilly Reports Solid First-Quarter Results
8. Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education
9. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
10. Lilly Announces Termination of AIR Insulin Program
11. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 21, 2013  MacroGenics, Inc. today announced that ... (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in ... oncoprotein," will be presented at the 2013 Annual ... during the Developmental Therapeutics - Immunotherapy Oral Abstract ... 4:30 PM.  The presentation will describe the results ...
(Date:5/21/2013)... Revolutionary Science, the manufacturer of the ... that they have expanded their colony counter product line ... InCount and ImpressCount. These affordable colony counters that ... food microbiology and pharmaceutical manufacturing. , The previously released ... bright white enclosure with jet black accents represent the ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Possible mold re-infestation ... so, according to a report from eagletribune.com posted May 14, ... In case the result is positive, My Cleaning Products offered ... harmful chemical ingredients. , It was said in the Eagle ... in the campus sparked after a first-grade classroom was ...
(Date:5/21/2013)... Clinovo's new “CDISC Standards: Theory and Application” ... June 11th, 2013. The TechTrainings are technical hands-on classes ... step in their professional career. The class will be ... online. , Taught by Sy Truong, President at Meta-Xceed ... Theory and Application” class will give an overview of ...
Breaking Biology Technology:MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2Possible Mold Re-infestation Gets Guilmette School Scheduled for Re-inspection, My Cleaning Products Offers Tip How to Kill Mold Safely If Inspection Turns Positive 2Possible Mold Re-infestation Gets Guilmette School Scheduled for Re-inspection, My Cleaning Products Offers Tip How to Kill Mold Safely If Inspection Turns Positive 3Clinovo Launches TechTrainings on CDISC Standards 2
... the University of Helsinki, Finland, has succeeded in producing ... is reduced to a nano-scale (one nanometre being one ... undergo substantial changes. Unlike in bulk materials, in nanoparticles ... the number of atoms inside the material, which, among ...
... Corporation (Amex: ETC ) ("ETC" or ... will be exhibiting at the upcoming APWCA 2009 ... (APWCA) 2009 National Conference will be held April ... Philadelphia, Center City. The APWCA provides cutting-edge education ...
... Portfolio LAKE FOREST, Ill., March 16 ... equity firm focused exclusively on the healthcare ... CorePharma LLC ("CorePharma") has completed the acquisition ... Leucovorin Calcium tablets are the generic equivalent ...
Cached Biology Technology:Paper electrified by copper particles 2Environmental Tectonics Corporation Announces Participation at APWCA National Conference 2Environmental Tectonics Corporation Announces Participation at APWCA National Conference 3RoundTable Healthcare Partners Facilitates Product Acquisition for CorePharma 2
(Date:5/21/2013)... types become most deadly when they metastasize and spread ... stage, it becomes very difficult for doctors to locate ... researchers at the University of Missouri have found a ... cells wherever they may be in the body. Michael ... College of Veterinary Medicine, says being able to target ...
(Date:5/21/2013)... of Illinois at Chicago College of Medicine will study gender ... its main energy source -- and how changes in fat ... $2 million, 4-year grant from the National Heart, Lung and ... uses fuel for energy. These changes may play a major ... in men and women, says E. Douglas Lewandowski, director of ...
(Date:5/21/2013)... -- Over the past few decades, scientists have developed ... balloons and metallic stents. While generally effective, each of ... effects. , A new study from MIT analyzes the ... benefits of angioplasty balloons and drug-releasing stents, but may ... is inflated in the artery for only a brief ...
Breaking Biology News(10 mins):MU researchers develop radioactive nanoparticles that target cancer cells 2Do men's and women's hearts burn fuel differently? 2Evaluating a new way to open clogged arteries 2Evaluating a new way to open clogged arteries 3
... have identified a subtype of ovarian cancer able to build ... especially susceptible to "anti-angiogenic" drugs that block blood vessel formation. ... PloS ONE , the investigators estimate that the subtype may ... common cancer of the surface of the ovaries. The ...
... AUSTIN, Texas Chemists at The University of Texas at ... inside the double helix of a DNA sequence that it can ... itself, much longer than any other molecule reported. It,s an ... go after rogue DNA directly. Such drugs would be revolutionary in ...
... , The Springer journal Analytical and Bioanalytical Chemistry ... as the recipients of its Best Paper Award 2011. Rmpp ... in ABC on mass spectrometry imaging. The award, accompanied by ... scientists and to stimulate their research careers. The ABC Best ...
Cached Biology News:New subtype of ovarian cancer may be vulnerable to anti-angiogenic drugs 2New subtype of ovarian cancer may be vulnerable to anti-angiogenic drugs 3New molecule can tangle up DNA for more than 2 weeks 2ABC Best Paper Award 2011 goes to Andreas Römpp and Sabine Guenther 2
Phospho-C/EBPbeta (Thr235) Antibody...
Rat monoclonal [HK5.3] to B7 RP1 (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
COMING SOON: Anti-Mouse C5a Receptor (CD88), Clone 10/92 Monoclonal Antibody...
... ( Abpromise for all tested applications). ... PVPKEMEQPV QTEEEDVELP conjugated to KLH, corresponding to ... melanogaster) SARA. Conserved sequence unique to ... 9372 Swiss Protein ...
Biology Products: